ZEISS Partners with Envision Health to Develop VR-Based Glaucoma Testing
Event summary
- ZEISS Medical Technology and Envision Health Technologies announced a strategic collaboration on June 18, 2026, to advance glaucoma care through VR-based visual function testing.
- The partnership combines ZEISS's expertise in perimetry with Envision's software-driven VR technologies.
- Dr. Lama A. Al-Aswad, founder of Envision Health Technologies, aims to improve accessibility and flexibility in glaucoma diagnostics.
- ZEISS generated €2.228 billion in revenue in fiscal year 2024/25.
The big picture
The collaboration between ZEISS and Envision Health Technologies reflects a broader industry shift towards digital health solutions that enhance patient accessibility and clinical efficiency. With growing demand for flexible, software-driven diagnostic tools, this partnership positions both companies to lead in the evolving landscape of glaucoma care. ZEISS's established market presence and Envision's innovative VR technologies create a formidable combination to drive advancements in visual function testing.
What we're watching
- Market Adoption
- How quickly clinicians and patients will embrace VR-based glaucoma testing as a standard diagnostic tool.
- Regulatory Approval
- Whether the collaboration will secure necessary regulatory approvals to deploy the technology globally.
- Competitive Response
- How existing players in the ophthalmology space will react to this innovative approach to glaucoma care.